Critical Contrast: bioAffinity Technologies (BIAF) versus Its Competitors

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its competitors? We will compare bioAffinity Technologies to similar businesses based on the strength of its analyst recommendations, valuation, dividends, profitability, institutional ownership, earnings and risk.

Profitability

This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.49%	-18.82%	-11.21%

Insider and Institutional Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares bioAffinity Technologies and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.63
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	8.94

bioAffinity Technologies’ competitors have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 6.02, indicating that their average share price is 502% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for bioAffinity Technologies and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	817	1306	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 13.21%. Given bioAffinity Technologies’ competitors higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its competitors.

Summary

bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.